Equibles does not estimate personal net worth.
Get an email with a short summary when Summit Therapeutics Inc. publishes a filing, an earnings call transcript or a press release.
Get SMMT alertsManmeet Soni is recorded as Board Member at Summit Therapeutics Inc. (SMMT) since January 1, 2019 and CFO and COO at Summit Therapeutics Inc. (SMMT). The newest filing on record that lists Manmeet Soni as CFO and Board Member at Summit Therapeutics Inc. (SMMT) is dated April 17, 2026. Summit Therapeutics Inc. reported in an 8-K filed April 3, 2024 that Manmeet Soni was appointed Chief Financial Officer, effective April 2, 2024. The proxy statement of Summit Therapeutics Inc. reports total compensation of $249,127,782 for Manmeet Soni in fiscal 2025, including a base salary of $616,500. Disclosed compensation is on record for 3 fiscal years. Manmeet Soni has spoken on 7 earnings calls and 1 other investor event across 1 company, most recently for Summit Therapeutics Inc. on July 23, 2026. Summit Therapeutics Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Summit Therapeutics Inc. includes Glyn Edwards (CEO), Mahkam Zanganeh (CEO, COO and Board Member), Robert Duggan (CEO and Board Member) and 7 others.
“In order to replace Mr. Dhingra, contemporaneously with Mr. Dhingra’s resignation, the Company appointed its Chief Operating Officer Manmeet Soni to the office of Chief Financial Officer, in which capacity he will serve as the Company’s principal financial officer, in addition to his continuing service as Chief Operating Officer.”
“On the financial front, let me start with our cash position. We ended the second quarter of 2026 with a strong cash position of approximately $690.7 million as compared to $598.7 million at the end of first quarter of 2026.”
“So we have been pretty, you know, efficient in our capital allocation, right? Running four phase threes by ourselves, our run rate for last quarter was $120 million.”
“On the financials front, let me start with our cash position. We ended the year 2025 with a strong cash position of approximately $713.4 million. And to remind everyone, currently we have no debt.”
“Today, in addition to providing you an update on our cash position and operating expenses, I will also provide color on our clinical operations. Let me start with an update on the clinical operations product.”
“We issued this afternoon our earnings release for the first quarter of 2025. Today, in addition to providing you with an update on our cash position and operating expenses, I will also provide you color on our clinical, commercial, and manufacturing operations.”
2019-01-01–present
Last confirmed April 17, 2026
Start not stated–present
Last confirmed April 17, 2026
Biotechnology · Healthcare
CFO, COO, Board Member
2019-01-01–present
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Summit Therapeutics Inc. (SMMT) | Chief Operating Officer, Chief Financial Officer and Director | $616,500 | $249,127,782 |
| 2024 | Summit Therapeutics Inc. (SMMT) | Chief Operating Officer, Chief Financial Officer and Director | $600,000 | $4,772,489 |
| 2023 | Summit Therapeutics Inc. (SMMT) | Chief Operating Officer, Chief Financial Officer and Director | $100,000 | $23,613,339 |
